N/A N=33 The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold
Common Cold
Primary: Reduction in Viral Load in the URT — 3.6; 3.3; 4.9; 4.1 log 10 copies/mL — p=0.7146
N/A N=334 Effect of Probiotic on Rhinovirus Induced Colds
Common Cold
Primary: Number of Participants With Rhinovirus-associated Illness Episodes — 63; 60 Participants
Phase 2 N=411 Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses
Common Cold
Primary: The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses. — 47.1; 43.9 cold illnesses per 100 subjects — p=>0.5000
Phase 2 N=171 To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold
Common Cold
Primary: Average Nasal Symptom Score Over Days 1-4 (ANSS1-4) — 3.428; 3.336 Score on a scale — p=0.516
N/A N=543 Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
Common Cold
Primary: Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. — 7.6; 9.5 Number of days — p=0.023
Phase 2 N=146 A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold
Common Cold
Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
Phase 4 N=84 Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds
Upper Respiratory Infection
Primary: Nasal Secretion Weights — 3.5; 4.2; 1.2; 2.6 grams
Phase 1 N=36 A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With Colds With at Least Moderate Intensity — 4; 2; 7; 0 Participants
Phase 4 N=72 Effects of a Common Cold Treatment on Cognitive Function
Common Cold
Primary: Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test — 4.8; 1.3 Valid responses — p=0.0008
Phase 4 N=200 Iota-Carrageenan Nasal Spray in Common Cold
Common Cold
Primary: Total Symptom Score (TSS) Over Days 2 to 4 (TSS2-4) — 6.390; 5.777 units on a scale — p=0.0895
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 2 N=200 Effect of Paracetamol on the Common Cold
Common Cold
Primary: Breathing Scores Post 15 Minutes — 0.83; 0.11 Score on a Scale — p=<0.0001
N/A N=49 Homeopathic Cold Medicine for Children
Upper Respiratory Tract Infection
Primary: Relief of Upper Respiratory Tract Infection (URI) Symptoms (Cough, Runny Nose, Nasal Congestion, Sneezing)1 Hour After Dose of Homeopathic Remedy. — 83; 100; 94; 52 doses
N/A N=263 Homeopathic Cold Remedy for Children Study
Upper Respiratory Tract Infections
Primary: Change in Severity of Cold Symptoms — 3.7; 3.7; 3.9; 3.9 units on a scale — p=.86
Phase 2 N=311 Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
Asthma · Common Cold · Picornavirus Infection
Primary: Percentage of Participants With Rhinovirus PCR-Positive Colds — 2.6; 2.5 percentage of participants — p=0.973
Phase 3 N=1,756 Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Enterovirus · Rhinovirus
Primary: Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) — 122.5; 137.1 hours — p=0.4009
Phase 4 N=53 The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
Common Cold
Primary: Symptom Severity Assessment at 15 Minutes — 10.66; 10.64; -1.11; -1.13 Score on scale — p=0.9473
Phase 2 N=70 Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
Common Cold Associated With Cough
Primary: Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours) — 6.92; 6.51 log-transformed total cough count
N/A N=200 BАbykids Spray In Common Cold
Common Cold · Rhinitis Viral
Primary: The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Full Analysis Set…
Phase 1 N=25 An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
Herpes Labialis
Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061
Phase 3 N=341 Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Upper Respiratory Tract Infection · Nasal Congestion · Rhinorrhea
Primary: Physician Global Evaluation of Effectiveness on Nasal Symptoms — 1.9; 2.1 score on a scale
Phase 2 N=300 A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Rhinovirus
Primary: Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire — -9.12; -5.11 Scores on a scale — p=0.020
N/A N=200 Testing the Efficacy in Adults With Cold of HEalsea Rescue*
Common Cold
Primary: AUC (Area Under Curve) of Wisconsin Upper Respiratory Symptom Survey (WURSS-21) During First 8 Days of Symptoms as Compared Between Both Groups - Full Analysis Set (FAS)…
N/A N=190 Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Common Cold
Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
Phase 2 N=40 Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
Upper Respiratory Tract Infections
Primary: Respiratory Infectious Symptoms — 9; 13; 10; 13 days — p=>0.05
Phase 2 N=378 Mucinex Exploratory Cold Study
Common Cold
Primary: Investigator's End of Study Assessment of Treatment — 163; 149 participants — p=0.0096
Phase 2 N=200 Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
Upper Respiratory Tract Infections
Primary: Frequency of Influenza-like Illness — 54; 62; 16; 28 participants — p=0.25